In the quiet evolution of personal health technology, Samsung has extended the reach of its Galaxy Watch 3 and Active 2 into territory once reserved for clinical settings — offering wrist-based blood pressure monitoring to everyday users. The feature, arriving in late February 2021, relies on pulse wave analysis rather than direct pressure measurement, and asks users to anchor its accuracy with monthly calibrations using a traditional arm cuff. It is a meaningful step in the long-running pursuit between Samsung and Apple to define what a smartwatch can mean for human wellbeing.
Screen Rant
· Feb 23, 2021
· technology
· 3 min de lectura
High
Verificación: Verificado
Samsung Galaxy Watch 3 & Active 2 Now Offer Blood Pressure Monitoring
◉
Technology
8948 artículos relacionados
Google Launches Gemini Enterprise for Legal Services
Google News · 100% coincidencia
Apple sues OpenAI for orchestrated trade secret theft campaign
CNA · 99% coincidencia
Musk accuses Apple of antitrust violation for favoring OpenAI in App S…
Livemint · 99% coincidencia
Musk's xAI sues Apple and OpenAI over alleged AI app favoritism
Breitbart News Network · 99% coincidencia
Musk Files Antitrust Lawsuit Against Apple and OpenAI Over AI Competit…
Devdiscourse · 99% coincidencia
Cobertura Relacionada
CBS News · Aug 28
Judge blocks Trump administration's 'retaliatory' punishment of AI firm Anthropic
A federal judge ruled the Trump administration unconstitutionally punished AI firm Anthropic for protected speech by cut…
NPR · Aug 28 Judge rules Pentagon's retaliation against Anthropic over AI criticism illegalA federal judge ruled Thursday that the Pentagon illegally punished AI company Anthropic for criticizing the Department …
Manila Bulletin · Aug 28 Lucena inventor demonstrates trash-collecting robot made from recycled materialsAn electronics technician in Lucena City created a remote-controlled garbage-collecting robot from recycled materials to…
The Guardian · Aug 28 Federal judge strikes down Pentagon's unlawful blacklisting of AI firm AnthropicA federal judge ruled the Trump administration's sanctions against AI company Anthropic were illegal retaliation for cri…
Sesgo y Encuadre
⚖
Article presents Samsung's blood pressure feature as a competitive achievement with neutral product coverage, though framing emphasizes Samsung's catch-up narrative to Apple.
Bias Direction
center
Confidence
MED
Competitive narrative framing that positions Samsung's feature launch within a historical Apple-Samsung rivalry context, emphasizing Samsung's delayed response to Apple's ECG capability as a 'big win' and 'catch-up' moment.
big win for Samsung
quickly overtook the market
distanced itself even further
looking to move beyond
User experience or reliability comparisons with Apple Watch blood pressure monitoring
Medical professionals' assessment of the pulse wave analysis method vs. traditional cuff measurement
Competitor perspectives (Fitbit, Garmin, etc.) on their blood pressure monitoring capabilities
Privacy/data security considerations for health monitoring features
Cost comparison with competing smartwatches offering similar features
Impacto Geopolítico
🌎
This article discusses Samsung's consumer smartwatch health feature and has no geopolitical implications.
Escalation Risk
low
Confidence
HIGH
Lente Económico
📈
Samsung's blood pressure monitoring feature on Galaxy Watch 3/Active 2 strengthens its wearables market position against Apple, potentially driving device sales and expanding health-tech ecosystem adoption.
Market Signal
bullish
Confidence
HIGH
Consumer Electronics & Wearables
Healthcare Technology
Digital Health Services
Smartphone Manufacturing
Consumers gain affordable continuous health monitoring without additional devices, reducing healthcare friction and encouraging wearable adoption. However, monthly calibration requirement creates ongoing engagement but may frustrate users seeking full autonomy.
Regulatory scrutiny likely regarding medical device classification, data privacy for health information, and accuracy standards. FDA clearance precedent suggests Samsung will pursue formal medical device validation, potentially enabling insurance reimbursement and clinical adoption.